BBZA Stock Chart & Stats
€54.50
€1.10(2.01%)
At close: 4:00 PM EDT
€54.50
€1.10(2.01%)
Day’s Range― - ―
52-Week Range€34.00 - €60.80
Previous CloseN/A
Volume6.47K
Average Volume (3M)14.33K
Market Cap
€3.26B
Enterprise Value-€387.73
Total Cash (Recent Filing)€3.08B
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)2.3
Beta0.70
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.07%
Share Statistics
EPS (TTM)24.50
Shares Outstanding55,149,250
10 Day Avg. Volume15,933
30 Day Avg. Volume14,333
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.89
Price to Sales (P/S)32.10
P/FCF Ratio7.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet gives BB Biotech substantial financial flexibility and reduces exposure to refinancing costs. The high equity-to-assets position supports resilience through biotech market cycles and allows the company to maintain its investment strategy without material leverage pressure.
Strong Current ProfitabilityThe sharp return to strong profitability provides a substantial earnings base for the investment company. If portfolio gains remain supported by successful biotech holdings, this performance can strengthen capital resources and support continued participation in attractive sector opportunities.
Positive Cash GenerationMeaningful operating and free cash flow since 2023 indicates that recent portfolio activity has translated into cash resources, not only accounting gains. This improves funding flexibility for investments, distributions, and portfolio management over the medium term.
Bears Say
Highly Volatile Earnings ProfileBB Biotech’s earnings depend on changes in portfolio values and realized investment outcomes, so results can vary sharply between periods. The history of losses followed by a strong rebound reduces visibility and makes medium-term earnings sustainability difficult to assess.
Uneven Cash-flow TrajectoryAlthough current cash generation is positive, the decline from the prior period and earlier negative years show that cash conversion is cyclical. This variability can constrain the consistency of distributions and investment capacity when portfolio exits or gains weaken.
Dependence On Biotech OutcomesThe company has no diversified operating revenue base; its returns rely on a concentrated biotech portfolio. Clinical failures, regulatory setbacks, weak commercialization, or poor position sizing can therefore materially impair results and remain a persistent business risk.
BB Biotech News
BBZA FAQ
What was BB Biotech AG’s price range in the past 12 months?
BB Biotech AG lowest stock price was €34.00 and its highest was €60.80 in the past 12 months.
What is BB Biotech AG’s market cap?
BB Biotech AG’s market cap is €3.26B.
When is BB Biotech AG’s upcoming earnings report date?
BB Biotech AG’s upcoming earnings report date is Oct 23, 2026 which is in 53 days.
How were BB Biotech AG’s earnings last quarter?
BB Biotech AG released its earnings results on Jul 24, 2026. The company reported €8.804 earnings per share for the quarter, beating the consensus estimate of N/A by €8.804.
Is BB Biotech AG overvalued?
According to Wall Street analysts BB Biotech AG’s price is currently Overvalued.
Does BB Biotech AG pay dividends?
BB Biotech AG pays a Annually dividend of €2.431 which represents an annual dividend yield of 4.07%. See more information on BB Biotech AG dividends here
What is BB Biotech AG’s EPS estimate?
BB Biotech AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BB Biotech AG have?
BB Biotech AG has 55,149,250 shares outstanding.
What happened to BB Biotech AG’s price movement after its last earnings report?
BB Biotech AG reported an EPS of €8.804 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.869%.
Which hedge fund is a major shareholder of BB Biotech AG?
Currently, no hedge funds are holding shares in DE:BBZA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BB Biotech AG
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. This fund allocates capital to publicly traded companies worldwide, with a primary focus on firms pioneering modern biotechnology, specifically in the development of medications and diagnostic tools. The construction of its investment portfolio is guided by a fundamental analysis approach. Established on November 9, 1993, BB Biotech AG is headquartered in Switzerland.
Technical Analysis
Basilea Pharmaceutica
―
Idorsia Ltd
―
Bachem Holding AG
―
PolyPeptide Group AG
―
Roche Holding Ltd
―